Thierry Bernard is the CEO at QIAGEN. Mr. Bernard joined QIAGEN in February 2015 to lead QIAGEN’s growing presence in molecular diagnostics. Mr. Bernard previously held multiple roles at bioMerieux for fifteen years, most recently as Corporate Vice President, Global Commercial Operations, Investor Relations and the Greater China Region. Prior to joining bioMerieux, he served in management roles in multiple international environments. Mr. Bernard is a member of the Boards of Directors of First Light Biosciences. He has earned degrees from Sciences Po (Paris), Harvard Business School, London School of Economics and the College of Europe, and is a member of French Foreign Trade Advisors.
Check out our latest #whitepaper containing clinical trial data, real-world evidence, and example algorithms that detail how T2Candida can be incorporated into practice and improve care for invasive candidiasis in your own practice.
- March 31, 2023